Syndax Pharmaceuticals (SNDX) had recently failed a phase 3 study using its drug entinostat plus exemestane, to treat patients with advanced HR+/HER2- breast cancer who had progressed on a non-steroidal aromatase inhibitor. This study failed to meet the primary endpoint of overall survival and thus the drug can't be advanced for this indication. While this is a huge blow to the company, I believe there is more value with an earlier stage drug known as SNDX-5613. This drug recently showed positive results in a phase 1 study in several patients. If this drug